NexGard Chewables for Dogs 24.1-60 lbs (10.1-25 kg)

Description

NexGard Chewables for Dogs 24.1–60 lbs (10.1–25 kg) delivers 68 mg afoxolaner per beef-flavored soft chewable, formulated by Boehringer Ingelheim Animal Health to provide the labeled minimum dosage of 1.14 mg/lb (2.5 mg/kg) across this mid-to-large weight band. A single monthly oral dose kills adult fleas within 4 hours of administration and controls six tick species through 30 days of sustained systemic afoxolaner activity.

Recommended for

Dogs and puppies weighing 24.1 to 60 lbs (10.1 to 25 kg), from 8 weeks of age.

Indication/Coverage

For dogs suffering from, or at risk from, flea and tick infestations, NexGard Chewables 24.1–60 lbs carries the following FDA-approved indications:

• Flea treatment (Ctenocephalides felis, adults): Afoxolaner achieves greater than 99% adult flea kill at 8 hours post-administration in controlled laboratory conditions; Boehringer Ingelheim field data confirm 98.0% efficacy at Day 30 and 99.9% at Day 90 against established infestations.
• Flea infestation prevention (Ctenocephalides felis): Sustained systemic afoxolaner concentrations over the 30-day interval eliminate adult fleas before oviposition, interrupting the flea life cycle and preventing environmental reinfestation.
• Treatment and control of Ixodes scapularis (black-legged tick, adults): Greater than 94% efficacy at 48 hours post-infestation maintained across a 30-day study period in controlled laboratory conditions.
• Treatment and control of Dermacentor variabilis (American dog tick, adults): Greater than 97% efficacy demonstrated at 48 hours post-infestation for 30 days.
• Treatment and control of Amblyomma americanum (lone star tick, adults): Greater than 97% efficacy recorded at 72 hours post-infestation through Day 30.
• Treatment and control of Amblyomma maculatum (Gulf Coast tick, adults): 97% efficacy at 72 hours post-infestation sustained to Day 31.
• Treatment and control of Rhipicephalus sanguineus (brown dog tick, adults): Greater than 93% efficacy at 48 hours post-infestation for 30 days.
• Treatment and control of Haemaphysalis longicornis (longhorned tick, adults): Greater than or equal to 98.5% efficacy at 72 hours post-infestation.
• Prevention of Borrelia burgdorferi infection: FDA-approved indication confirmed across two controlled laboratory studies; protection is mechanistically dependent on elimination of Ixodes scapularis vector ticks before pathogen transmission occurs.

Key Benefits

The attributes listed below reflect data from the FDA-approved product label and Boehringer Ingelheim clinical studies for the 24.1–60 lb dosing variant:

• Covers from 8 weeks: Dogs and puppies weighing at least 24.1 lbs from 8 weeks of age are eligible for this chewable, extending isoxazoline-class flea and tick protection into the mid-to-large puppy bracket without requiring a separate juvenile product.
• Six tick species in one dose: A single monthly chewable addresses Ixodes scapularis, Dermacentor variabilis, Amblyomma americanum, Amblyomma maculatum, Rhipicephalus sanguineus, and Haemaphysalis longicornis, covering all tick species of primary clinical relevance across U.S. geographic ranges.
• Flea kill at 4 hours: Afoxolaner reaches systemic circulation and begins eliminating adult fleas at 4 hours post-administration; greater than 99% flea kill is recorded at 8 hours in laboratory conditions, limiting adult flea survival time on treated animals.
• Sustained 30-day activity: The 68 mg afoxolaner dose maintains parasiticidal plasma concentrations throughout the full monthly dosing interval, with laboratory and field data confirming efficacy through Day 30 and Day 31 across multiple tick species.
• Egg deposition halted after first dose: Fleas on afoxolaner-treated dogs are rendered incapable of producing viable eggs at post-infestation evaluations following initial dosing, breaking the flea reproductive cycle in the home environment.
• Oral route removes application error risk: Dogs in the 24–60 lb range frequently carry double coats or dense undercoats that obstruct accurate spot-on placement; oral administration as a chewable bypasses fur thickness, coat type, and skin-contact requirements entirely.
• Lyme disease prevention labeled by FDA: The explicit Borrelia burgdorferi prevention indication on the NexGard label is a regulated clinical claim, not a general marketing statement, and applies to dogs in this weight range at the standard monthly dosing interval.
• Documented co-administration safety: Two US field studies recorded NexGard administered alongside vaccines, anthelmintics, antibiotics, steroids, NSAIDs, anesthetics, and antihistamines without adverse interactions, providing a reference record for dogs in this size category that commonly carry concurrent preventative regimens.

Caution

Hazards to Humans

NexGard is not formulated for human use. Keep out of reach of children and away from food contact surfaces. In the event of accidental ingestion by a person, contact a physician without delay. Wash hands after handling the chewable.

Hazards to Domestic Animals

Administer NexGard orally to dogs only; do not use in cats or other animal species. This variant is labeled for dogs and puppies weighing 24.1 to 60 lbs (10.1 to 25 kg) from 8 weeks of age. Dogs below 24.1 lbs on the dosing day require a lower weight-band variant. Consult a veterinarian before use in debilitated, aged, pregnant, or lactating dogs, as safety in these categories has not been fully evaluated. Afoxolaner is an isoxazoline-class compound; use with caution in dogs with any history of seizures or neurological disorders, as seizures have been reported in dogs receiving isoxazoline-class drugs even without a prior seizure history.

Possible Side Effects

Monitor your dog after each administration, with close attention during the first dosing cycle. The reactions below are drawn from Boehringer Ingelheim’s 90-day US field study involving 415 afoxolaner-treated dogs and from post-approval adverse drug experience reports submitted to FDA/CVM.

• Vomiting: Recorded in 4.1% of afoxolaner-treated dogs in the field study, making it the most frequently observed adverse reaction; occurrence generally declined with subsequent monthly doses. Redose with a complete replacement chewable if vomiting takes place within 2 hours of administration.
• Diarrhea (with or without blood): Observed in 3.1% of dogs in the afoxolaner treatment group across the 90-day study period.
• Dry or flaky skin: Noted in 3.1% of treated dogs; the field study did not establish a dose-dependent relationship for this reaction.
• Lethargy: Reported in 1.7% of afoxolaner-treated dogs during the study interval.
• Anorexia: Documented in 1.2% of treated dogs; two of the five affected animals experienced reduced appetite only with the first dose and not on subsequent administrations.
• Seizures: Identified through post-approval adverse drug experience reporting to FDA/CVM. Two dogs with documented prior seizure histories experienced seizure events on the day of dosing in the US field study; this risk applies to the isoxazoline class broadly.
• Additional post-approval reactions (decreasing reporting frequency): Pruritus, hyperactivity or restlessness, panting, erythema, ataxia, dermatitis including rash and papules, allergic reactions including hives and swelling, and tremors.